KBC Securities - Autolus Therapeutics ADS (AUTL) Autolus RD day outlines SLE data and path to market, MS up next

Report

KBC Securities

Jacob Mekhael

Autolus R&D day outlines SLE data and path to market, MS up next

Yesterday, Autolus hosted an R&D day where it shared initial data from the phase 1 trial of obe-cel (CD19 CAR-T) in r/r SLE which showed that 3/6 patients achieved complete renal response (CRR). The company has aligned with the FDA on the route to market, and plans to initiate a pivotal phase 2 trial by YE25. In addition, Autolus announced its plan to evaluate obe-cel in progressive MS with a dose escalation trial due to begin by YE25. We reiterate our $ 10 TP and Buy rating.

24/04/2025 1 EN

Underlying

Autolus Therapeutics ADS

See profile

US05280R1005 NASDAQ Stock Market United Kingdom

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

Autolus Longer follow up at EHA maintains Aucatzyl's benefit in r/r adult ALL

Autolus announced updated long term data (approx. 3 years of follow up) from the phase 2 (FELIX) study of Aucatzyl (CD19 CAR-T) in r/r adult ALL to be presented at the European Hematology Association (EHA) conference, being held 12-15 June. The updated results demonstrate that Aucatzyl has maintained its benefit without the need for additional therapy with an additional 11 months of follow up as 38.4% of responders are in ongoing remission (vs. 40% at 21.5 months median follow up). We believe those outcomes support the efficacy differentiation of Aucatzyl on top of its well established safety ...

June 12, 2025 June 12, 2025 1 EN

KBC Securities

Morning Notes : BESI NA, EVS BB, UCB BB, AUTL US

: BESI NA, EVS BB, UCB BB, AUTL US

June 12, 2025 June 12, 2025 1 EN

GlobeNewsWire

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow upMore than half of patients still in remission at 24 months38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel LONDON, June 12, 2025 (GLOBE NEWSWIRE...

June 12, 2025 June 12, 2025 1 EN

Brederode 1Q25: NAVps down 1.7%; Weakening Dollar Impacts Private Assets

Over 1Q25, NAVps decreased by 1.7% to €139.0ps (vs. €141.4ps at FY24-end). This was mainly due to the private asset portfolio, which recorded a loss of €74.7m on the ~€4.1bn portfolio. The primary reason was the recent decline of the USD. The listed assets generated a modest €6.6m gain, mostly driven by Iberdrola and Enel. During the first quarter, the position in Experian was strengthened, while the position in Nestlé was reduced. We currently estimate the NAVps at €140.0, implying a 13.2% discount. This is higher than the 5yr average of 11.4%, but lower than the more relevant 2yr average of ...

June 13, 2025 June 13, 2025 1 EN

Jacob Mekhael

Jacob Mekhael

Galapagos Updated NHL phase 1/2 GLPG5101 data at EHA shows decentralised POC

Galapagos will present new data from the ongoing Phase 1/2 (ATALANTA-1) study of GLPG5101 (CD19 CAR-T) at the European Hematology Association (EHA) Congress, being held 12-15 June. The results demonstrate POC for a 7 day vein-vein de-centralised CAR-T manufacturing process. Combined with the previously reported safety differentiation, we believe this could support strategic discussions as the company is exploring such options for its cell therapy business. We reiterate our Buy rating and € 37 TP.

June 13, 2025 June 13, 2025 1 EN

Jacob Mekhael

Jacob Mekhael

MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent outcomes

MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient population where no current standard of care exists. With regulatory submission in Europe completed,...

June 13, 2025 June 13, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Autolus R&D day outlines SLE data and path to market, MS up next

We are a financial services provider for several types of professional clients, each with distinct needs.

Autolus Longer follow up at EHA maintains Aucatzyl's benefit in r/r adult ALL

Morning Notes : BESI NA, EVS BB, UCB BB, AUTL US

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Brederode 1Q25: NAVps down 1.7%; Weakening Dollar Impacts Private Assets

Galapagos Updated NHL phase 1/2 GLPG5101 data at EHA shows decentralised POC

MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent outcomes

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe